Read More Pharma Industry News Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a… byPallavi MadhirajuMarch 6, 2025